How to Buy Rhythm Pharmaceuticals Stock
Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc. , a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity.
Rhythm Pharmaceuticals stock last closed at $85.58, up 4.61% from the previous day, and has increased 32.87% in one year. It has overperformed other stocks in the Biotechnology industry by 0.5 percentage points. Rhythm Pharmaceuticals stock is currently +54.73% from its 52-week low of $55.31, and -29.97% from its 52-week high of $122.20.
At the moment, there are 68.29M RYTM shares outstanding. The market capitalization of RYTM is $5.84B. In the past 24 hours, 1.28M RYTM shares were traded.
How to Buy Rhythm Pharmaceuticals Stock
Not sure how to invest in Rhythm Pharmaceuticals stock? Here's how.
- Figure out where to buy Rhythm Pharmaceuticals stock: You need to decide on a stock brokerage, but don't worry - we've tried dozens of stock brokerages and apps to help you figure out where to buy Rhythm Pharmaceuticals stock.
- Sign up for your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
- Fund your investment account: Pick your method of payment and add your info.
- Research Rhythm Pharmaceuticals stock: The Rhythm Pharmaceuticals ticker symbol is RYTM. Is Rhythm Pharmaceuticals stock a good investment? Should you buy shares of RYTM? How do RYTM's underlying business fundamentals look? Do top analysts think Rhythm Pharmaceuticals is a good buy? Why has RYTM's stock price moved recently? (Hint: Our stock market research website can help you decide if RYTM is a good stock to buy).
- Execute your RYTM purchase: Decide if you will purchase RYTM shares at the current market price or use a limit order to purchase RYTM shares at a given price.
- Keep an eye on your investment in RYTM: Create a watchlist to get live updates on your new investment in Rhythm Pharmaceuticals stock.
Step 1: Figure out where to buy Rhythm Pharmaceuticals stock
You need an online brokerage account to access the NASDAQ market and buy RYTM shares.
Our favorite brokerage: eToro
In our opinion, eToro is the best place to buy stocks. Here's why:
- You can invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
- Access to world markets: From Tech to Energy, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's leading exchanges.
- Social investing: eToro offers a community of more than 20 million users worldwide. Talk to, learn from, and copy the crypto trades of other investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your stock purchase by creating an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Sign up for your brokerage account
Now that you've chosen the best brokerage, you need to fill out some personal information so you are able to invest in RYTM stock today.
How to Open a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal details to start a new trading account.
- Submit your details by pressing the "Create Account" button. Get started with eToro today
Step 3: Fund your investment account
Now that you've finished signing up on one of the most highly reviewed stock trading apps, you can securely and quickly fund your account:
Check out the walkthrough below for more details depositing funds into your investment account.
Step 4: Research Rhythm Pharmaceuticals stock
Once you have figured out the best place to buy Rhythm Pharmaceuticals stock, it's very important to research their stock before you buy, so you can wrap your head around the risk and upside.
Rhythm Pharmaceuticals Numbers
RYTM Due Diligence Checks
WallStreetZen was created to help everyday investors perform better fundamental analysis.
You can view all of the due diligence checks on RYTM's stock page.
Is RYTM stock properly valued?
Investors use many financial metrics, analyses, models, and charts to gauge RYTM's intrinsic value.
Using relative valuations metrics:
- RYTM could be overvalued based on its P/B ratio of 42.02x, relative to Biotechnology industry P/B ratio of 5x
You can do more valuation analysis on RYTM's stock here.
A look at RYTM Cashflows and Balance Sheet
Positive Health Checks:
- RYTM has cash burn of 116628000. It has enough cash and short-term investments to cover this for at least one year.
- RYTM has $389.47M in cash and short term investments. This is enough to cover its annual cash burn of $116.63M.
- There are more short-term assets than long-term liabilities on the RYTM balance sheet.
- There are more short-term assets than short-term liabilities on the RYTM balance sheet.
Negative Health Checks:
- RYTM has a relatively high debt to equity ratio of 1.51.
- RYTM profit margin has gone up by 0.97 percentage points in the past year, but the company is still unprofitable.
- Total RYTM debt is higher than 5 years ago, relative to shareholder equity.
Is it a good time to buy RYTM stock, according to analysts?
Out of 11 sell side analysts who research RYTM, the consensus analyst rating on Rhythm Pharmaceuticals is a Strong Buy
Please keep in mind that analyst ratings are not stock recommendations, nor are they financial advice.
Latest RYTM Analyst Upgrades/Downgrades
Jeffrey Hung, a top 7% analyst from Morgan Stanley maintains RYTM with a strong buy rating and lowers their RYTM price target from $150.00 to $136.00, on Mar 17, 2026.
Joseph Stringer, a top 2% analyst from Needham maintains RYTM with a buy rating and lowers their RYTM price target from $139.00 to $130.00, on Mar 17, 2026.
Derek Archila, a top 3% analyst from Wells Fargo maintains RYTM with a strong buy rating and raises their RYTM price target from $136.00 to $143.00, on Mar 12, 2026.
Wells Fargo's Derek Archila raised their price target on Rhythm Pharmaceuticals (NASDAQ: RYTM) by 5.1% from $136 to $143 on 2026/03/12. The analyst maintained their Strong Buy rating on the stock.
Rhythm Pharmaceuticals reported its Q4 and FY 2025 earnings.
Archilla said that their price target hike was based on marginally higher revenue projections.
According to the analyst, their conversations with doctors representing early targets post-approval gave them more faith in the hypothalamic obesity launch of IMCIVREE and its peak opportunity.
Earnings Report
Rhythm Pharmaceuticals reported:
For Q4 2025:
- GAAP EPS of $(0.73), which beat the Zacks Consensus Estimate of $(0.79) but missed Q4 2024's $(0.72).
- Revenue of $57.25M, which beat the Zacks Consensus Estimate by 3.53% and Q4 2024's $41.83M.
For FY 2025:
- GAAP EPS of $(3.11), up from FY 2024's $(4.34).
- Revenue of $194.8M, up from FY 2024's $130.1M.
Management did not provide revenue and earnings guidance in its press release.
Chairman, President & CEO David Meeker, M.D., commented: “Rhythm delivered solid IMCIVREE global sales growth and made continued progress developing therapies to address hyperphagia and severe obesity for people with rare MC4R pathway diseases in 2025.
“We enter 2026 focused on long-term growth and well-capitalized to achieve important commercial and clinical milestones.
"We are prepared to bring IMCIVREE to patients with acquired HO in the United States, pending FDA approval.
“We continue to advance clinical development of our next-generation of MC4R pathway agonists to improve patients’ lives.
"Following a highly constructive end-of-phase-2 meeting with the FDA where we shared encouraging open-label extension data focused on our oral MC4R agonist bivamelagon, we remain on track to initiate a Phase 3 trial evaluating bivamelagon in acquired HO by year-end 2026.”
Whitney Ijem, a top 5% analyst from Canaccord Genuity maintains RYTM with a strong buy rating and lowers their RYTM price target from $141.00 to $140.00, on Mar 2, 2026.
Seamus Fernandez, a top 3% analyst from Guggenheim maintains RYTM with a strong buy rating and raises their RYTM price target from $140.00 to $143.00, on Feb 27, 2026.
You can dig deeper into what analysts are forecasting on the Rhythm Pharmaceuticals stock forecast page.
RYTM Technical Indicators
RYTM Earnings
Last year, RYTM revenue was $189.76M. During the last four year, RYTM's revenue has gone up by 178.51% per year. This was faster than the Biotechnology industry average of 26.5%.
Learn more about RYTM's earnings and revenue performance here.
What are RYTM insiders up to?
Over the past 12 months, executives and large shareholders at RYTM have sold more shares than they have bought.
Christopher Paul German, Corporate Controller CAO of RYTM, was the latest RYTM insider to buy. They bought $26,955.00 worth of RYTM shares on Mar 4, 2026.
Learn more about who owns RYTM stock here.
Does RYTM provide a stable income stream?
No, Rhythm Pharmaceuticals doesn't provide an income stream by paying out dividends.
What do other traders have to say about RYTM?
One of the biggest reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to see what other traders have to say.
Step 5: Execute your RYTM purchase
You have two primary types of orders:
- Market order: A market order is an order to buy or sell a stock at the best available price.
Market orders are mostly the best for newer investors. - Limit order: A limit order allows you to buy or sell a stock at a specific price (or better).
If you want to be certain you're buying or selling at a specific price limit, place a limit order.
Hit the Open button and your broker will place your order.
If you need additional info about investing in stocks on eToro, watch the helpful video below:
Step 6: Keep an eye on your investment in RYTM
Now that you own some shares in RYTM, you'll want to stay up-to-date on your new shares.
Start a watchlist to track the most important metrics related to your RYTM stock.
RYTM Feed
How to Buy Stock in Rhythm Pharmaceuticals
To reiterate, here are the 6 steps for buying Rhythm Pharmaceuticals stock:
- Figure out where to buy Rhythm Pharmaceuticals stock
- Sign up for your brokerage account
- Fund your investment account
- Research Rhythm Pharmaceuticals stock
- Execute your RYTM purchase
- Keep an eye on your investment in RYTM
If you require a place to buy stocks, eToro is our recommended venue.
Get Started with eToro TodayIf you would like to get updates on your investment in Rhythm Pharmaceuticals, add RYTM to your watchlist by clicking the button below.
More "How To" Guides You May Find Useful
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.